


S1900A
NOW OPEN

 **LUNG-MAP**



Dr. Jonathan Riess
UC Davis Comprehensive Cancer Center

Dr. Paul Wheatley-Price
Ottawa Hospital Cancer Centre



Rucaparib is a potent small-molecule inhibitor of poly (ADP-ribose) polymerase (PARP) proteins that help repair DNA damage and maintain genomic stability.

Sub-study **S1900A** of Lung-MAP seeks to **evaluate the response rate associated with rucaparib** in patients with genomic loss of heterozygosity high and/or deleterious BRCA 1/2 mutation-positive non-small cell lung cancer.

S1900A a biomarker-driven study is for patients with Stage IV or recurrent non-small cell lung cancer.

The expected monthly accrual rate is 4 per cohort. The estimated percentage of screened patients assigned to this study is 20% for both cohorts with response rates being estimated within 16%.

Rucaparib will be taken twice daily. Treatment will continue in consenting patients until disease progression or intolerable toxicity.

Rucaparib

Single-Arm Phase II Trial

LOH high and/or deleterious
BRCA 1/2 positive patients

21 Day Cycle Length
Oral Twice a Day

Questions:

Eligibility/Data Submissions:
LUNGMAPquestion@crab.org

Treatment/Toxicity:

S1900AMedicalQuery@swog.org

Protocol/Regulatory:

mnorman@swog.org